IP Library Granted Patent US 6,908,900
Granted Patent B2
US 6,908,900 · App. 10/050,903 · Granted Jun 21, 2005

COMPOSITIONS AND METHODS FOR ENHANCED PHARMACOLOGICAL ACTIVITY THROUGH ORAL AND PARENTERAL ADMINISTRATION OF COMPOSITIONS COMPRISING POLYPEPTIDE DRUG SUBSTANCES AND OTHER POORLY ABSORBED ACTIVE INGREDIENTS

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,908,900
App. No.
10/050,903
Granted
Jun 21, 2005
Kind
B2
Abstract

Disclosed herein are novel pharmaceutical agents and compositions, as well as novel methods, to enhance the absorption of polypeptide drug substances that normally display little if any absorbability if administered orally. Also disclosed are novel compositions and methods to significantly enhance the bioavailability and pharmacological efficacy of polypeptide drug substances whether administered orally or parenterally.

Claims (14)

1. A pharmaceutical agent comprising a carrier moiety and a therapeutically active peptide species, wherein the peptide has the formula aa n , where n is the number of amino acid residues in the peptide and wherein the carrier is a member selected from the group consisting of cinnamoyl, benzoyl, phenylacetyl, 3,4-methylenedioxycinnamoyl, 3,4,5-trimethoxycinnamoyl, t-butoxycarbonyl, benzyloxycarbonyl, pivaloyl, N-9-fluorenylmethoxycarbonyl, and fumaroyl.

2. The pharmaceutical agent of claim 1 , wherein the carrier moiety comprises an aryl or alkyl group of sufficient length or steric bulk to protect the active peptide species from enzymatic degradation in vivo.

3. The pharmaceutical agent of claim 1 , wherein the carrier moiety is chemically linked to a therapeutically active peptide species of the general formula aa n , where n is an integer from 2 to 40.

4. The pharmaceutical agent of claim 3 , wherein the polypeptide is poorly absorbed orally.

5. The pharmaceutical agent of claim 3 , wherein n is an integer from 3 to 6.

6. The pharmaceutical agent of claim 5 , wherein n is 5.

7. The pharmaceutical agent of claim 3 , wherein the therapeutically active peptide species comprises Tyr-Gly-Gly-Phe-Met.

8. A pharmaceutical composition for administration to a patient in need thereof comprising the pharmaceutical agent of claim 1 , and one or more pharmaceutically acceptable adjuvants.

9. The pharmaceutical composition of claim 8 , wherein the composition is formulated for oral administration.

10. The pharmaceutical composition of claim 8 , wherein the composition is formulated for parenteral administration.

11. The pharmaceutical composition of claim 10 , wherein the composition is formulated for intravenous administration.

12. The pharmaceutical composition of claim 8 , wherein the composition releases a biologically active form of the pharmaceutical agent into the patient's system at physiologically effective levels over a period of time of up to twelve hours.

13. The pharmaceutical composition of claim 8 , wherein the composition releases a biologically active form of the pharmaceutical agent into the patient's system at physiologically effective levels over a period of time of up to twenty-four hours.

14. The pharmaceutical composition of claim 10 , wherein the peptide species is an epitope or an immune sequence characteristic of an infectious, viral or cancerous disease.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2013
From: IMMUPHARMA (FRANCE) SA
To: UREKA SARL
Reel/Frame 030975/0522 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2007
From: IMMUPHARMA AG
To: IMMPHARMA SA
Reel/Frame 019215/0700 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2007
From: IMMUPHARMA AG
To: IMMUPHARMA SA
Reel/Frame 019147/0559 →
CHANGE OF NAME Recorded Apr 11, 2007
From: ZIMMER & ASSOCIATES AG/SA/LTD.
To: IMMUPHARMA AG
Reel/Frame 019140/0880 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2004
From: ZIMMER, ROBERT H.
To: ZIMMER & ASSOCIATES AG
Reel/Frame 014960/0815 →